Precision medicine by targeting PD-L1 variants for treatment of cancer
First Claim
Patent Images
1. A method of treating a solid tumor;
- melanoma;
renal cell carcinoma;
non small-cell lung cancer;
bladder cancer;
Hodgkin'"'"'s lymphoma;
or gastric cancer;
in a human, the method comprising administering to said human an anti-PD-L1 antibody or antibody fragment that specifically binds to a human PD-L1 that is expressed by a PD-L1 nucleotide sequence comprising a variation selected from the group consisting of;
rs148141792;
rs369350813;
rs10481593;
rs2282055;
rs2297135;
rs2297136;
rs2297137;
rs3780395;
rs7023227;
rs34028061;
rs7041009;
rs148170925;
rs10114060;
rs1536926; and
rs7042084;
wherein the antibody or antibody fragment that specifically binds to human PD-L1 comprises a human gamma-1 heavy chain constant region that comprises an amino acid selected from the group consisting of;
an Asp corresponding to position 204 of SEQ ID NO;
42 and a Leu corresponding to position 206 of SEQ ID NO;
42; and
wherein said human comprises;
(i) an IGHG1*01 human heavy chain constant region gene segment, or the human expresses antibodies comprising human gamma-1 heavy chain constant regions comprising said selected amino acid; and
(ii) a PD-L1 nucleotide sequence comprising said selected variation.
1 Assignment
0 Petitions
Accused Products
Abstract
The invention relates to human targets of interest (TOI), anti-TOI ligands, kits compositions and method.
-
Citations
15 Claims
-
1. A method of treating a solid tumor;
- melanoma;
renal cell carcinoma;
non small-cell lung cancer;
bladder cancer;
Hodgkin'"'"'s lymphoma;
or gastric cancer;
in a human, the method comprising administering to said human an anti-PD-L1 antibody or antibody fragment that specifically binds to a human PD-L1 that is expressed by a PD-L1 nucleotide sequence comprising a variation selected from the group consisting of;rs148141792;
rs369350813;
rs10481593;
rs2282055;
rs2297135;
rs2297136;
rs2297137;
rs3780395;
rs7023227;
rs34028061;
rs7041009;
rs148170925;
rs10114060;
rs1536926; and
rs7042084;
wherein the antibody or antibody fragment that specifically binds to human PD-L1 comprises a human gamma-1 heavy chain constant region that comprises an amino acid selected from the group consisting of;an Asp corresponding to position 204 of SEQ ID NO;
42 and a Leu corresponding to position 206 of SEQ ID NO;
42; and
wherein said human comprises;(i) an IGHG1*01 human heavy chain constant region gene segment, or the human expresses antibodies comprising human gamma-1 heavy chain constant regions comprising said selected amino acid; and (ii) a PD-L1 nucleotide sequence comprising said selected variation. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)
- melanoma;
Specification